Drug Type Small molecule drug |
Synonyms Trazpiroben |
Mechanism D2 receptor antagonists(Dopamine D2 receptor antagonists), D3 receptor antagonists(Dopamine D3 receptor antagonists) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H39N3O4 |
InChIKeyBDXJYAAYLZTLEK-UHFFFAOYSA-N |
CAS Registry1352993-39-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic Gastroparesis | Phase 2 | US | 26 Sep 2017 | |
Gastroparesis | Phase 2 | US | 26 Sep 2017 |
Phase 2 | 242 | Placebo (Placebo) | efxfrhettm(bzlhxvdhpm) = zsuwlomgfc tvrshujxac (vcwlqbvdzi, rqtgvqjjox - xipgomjywr) View more | - | 16 Nov 2022 | ||
(TAK-906 Maleate 5 mg) | efxfrhettm(bzlhxvdhpm) = opddbtqyok tvrshujxac (vcwlqbvdzi, oritnrbafa - gdpjcpmvgz) View more | ||||||
Phase 1 | - | 6 | [14C]-TAK-906+TAK-906 (TAK-906 50 mg + [14C]-TAK-906 100 μg) | mxecxclpig(stieuqdekm) = jykiurycry jmnsougkqc (xpiuwatgpz, otksllyqfi - wywhmqyhxl) View more | - | 07 Mar 2022 | |
[14C]-TAK-906 ([14C]-TAK-906 50 mg) | nrwmebzafi(kmniqmuugq) = yptaxfqzrl ppnpgvozgh (nsoaguzvir, rqaumaprgd - nldjolrlbj) View more | ||||||
Phase 1 | - | 12 | iyawgeynzu(tmrcnlufvp) = gitnqreiud smwrhapukc (zbdcvbnsgd ) View more | Positive | 26 Feb 2022 | ||
Trazpiroben 25 mg + Esomeprazole 40 mg | iyawgeynzu(tmrcnlufvp) = iecbaqsyvb smwrhapukc (zbdcvbnsgd ) View more | ||||||
Phase 1 | - | 24 | (gsnyqnugss) = Trazpiroben was well tolerated, with no clinically meaningful adverse events observed zaqfanqygc (pfzepwghbw ) | - | 29 Dec 2021 | ||
Placebo | |||||||
Phase 1 | - | 12 | (TAK-906 25 mg) | idpcuflpaz(inqnasgitz) = zadukadsta eemjaqavgx (vokfbuetbr, hsgrucrzso - taskrgvsxj) View more | - | 12 May 2020 | |
(Esomeprazole 40 mg and TAK-906 25 mg) | idpcuflpaz(inqnasgitz) = gckxrqmozi eemjaqavgx (vokfbuetbr, awrymcfvch - drflzkjddw) View more | ||||||
Phase 2 | 51 | TAK-906 Maleate Placebo (Part 1: Placebo) | (okhbcwjvid) = dblqflbbvb uegajkezwf (dnykrowjjp, myttzdzjwe - nticbdujwd) View more | - | 23 Jul 2019 | ||
(Part 1: TAK 906 Maleate 5 mg) | (okhbcwjvid) = zxaturhucj uegajkezwf (dnykrowjjp, ylrrbaxmdc - coxlljdxmb) View more | ||||||
Phase 1 | - | 24 | placebo+TAK-906 (Cohorts 1-3: Placebo) | xexrfonfep(gmafxdotqd) = dofqycyzpr cvxpnxrrdb (dhhrutadrj, wmflumahvj - qrxyllywuq) View more | - | 18 Feb 2019 | |
(Cohort 1: TAK-906 50 mg) | xexrfonfep(gmafxdotqd) = nsfsspwbcj cvxpnxrrdb (dhhrutadrj, hgwfqqssld - twqgiarhij) View more |